Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - insulinum lisprum - sospensione iniettabile - insulinum lisprum 100 u.i. corresp. insulinum lisprum 3.5 mg ut insulinum solutum 25 % et insulinum isophanum 75 %, protamini sulfas, glycerolum, zinci oxidum, dinatrii phosphas heptahydricus, metacresolum, phenolum, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile ad suspensionem pro 1 ml corresp. natrium 0.8 mg. - il diabete mellito - biotechnologika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - insulinum lisprum - sospensione iniettabile - insulinum lisprum 100 u.i. corresp. insulinum lisprum 3.5 mg ut insulinum solutum 50 % et insulinum isophanum 50 %, protamini sulfas, glycerolum, zinci oxidum, dinatrii phosphas heptahydricus, metacresolum, phenolum, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile ad suspensionem pro 1 ml corresp. natrium 0.8 mg. - il diabete mellito - biotechnologika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - lamivudinum - compresse rivestite con film - lamivudinum 100 mg, cellulosum microcristallinum, carboxymethylamylum natricum, magnesii stearas, Überzug: hypromellosum, macrogolum 400, polysorbatum 80, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 284 µg. - chronische epatite b - synthetika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - lamivudinum - soluzione orale - lamivudinum 5 mg, saccharum 200 mg, propylenglycolum 20 mg, natrii citras dihydricus, acidum citricum, natrii hydroxidum aut acidum hydrochloridum, aqua, propylis parahydroxybenzoas 180 µg, e 218 1.5 mg, aromatica corresp. propylenglycolum 44.8 µg et alcohol benzylicus 0.02 µg, aromatica corresp. propylenglycolum 18.6 µg et alcohol benzylicus 0.01 µg, ad solutionem pro 1 ml corresp. natrium 2.94 mg. - chronische epatite b - synthetika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

novo nordisk pharma ag - insulinum aspartum - soluzione iniettabile - insulinum aspartum 100 u. corresp. 3.5 mg, glycerolum, phenolum, metacresolum, zinci chloridum, natrii chloridum, dinatrii phosphas dihydricus, natrii hydroxidum ad ph, acidum hydrochloridum ad ph, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 1.9 mg. - il diabete mellito - biotechnologika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

novo nordisk pharma ag - insulinum aspartum - soluzione iniettabile - insulinum aspartum 100 u. corresp. corresp. 3.5 mg, glycerolum, phenolum, metacresolum, zinci chloridum, natrii chloridum, dinatrii phosphas dihydricus, natrii hydroxidum ad ph, acidum hydrochloridum ad ph, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 1.9 mg. - il diabete mellito - biotechnologika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - salbutamolum - dosier aerosol - salbutamolum 0.1 mg ut salbutamoli sulfas, acidum oleicum, ethanolum anhydricum, norfluranum, ad aerosolum pro dosi, doses pro vase 200. - bronchospasmolytikum - synthetika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - peginterferonum alfa-2b - injektionspräparat - praeparatio cryodesiccata: peginterferonum alfa-2b 50 µg, dinatrii phosphas, natrii dihydrogenophosphas dihydricus, saccharum, polysorbatum 80, pro vitro. solvens: aqua ad iniectabilia, q.s. ad solutionem pro 0.5 ml pro vitro. - chronische hepatitis c - biotechnologika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - peginterferonum alfa-2b - injektionspräparat - praeparatio cryodesiccata: peginterferonum alfa-2b 50 µg, dinatrii phosphas, natrii dihydrogenophosphas dihydricus, saccharum, polysorbatum 80. solvens: aqua ad iniectabilia q.s. ad solutionem pro 0.5 ml pro vitro. - chronische hepatitis c - biotechnologika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - peginterferonum alfa-2b - injektionspräparat - praeparatio cryodesiccata: peginterferonum alfa-2b 80 µg, dinatrii phosphas, natrii dihydrogenophosphas dihydricus, saccharum, polysorbatum 80. solvens: aqua ad iniectabilia q.s. ad solutionem pro 0.5 ml pro vitro. - chronische hepatitis c - biotechnologika